A Chronic Pain Master Protocol (CPMP): A Study of LY4065967 in Participants With Chronic Low Back Pain
Eli Lilly and Company · NCT07641504
Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.
Key facts
- Compensation
- Not posted. Ask the study team before screening.
- Who can join
- Ages 18+ · All sexes
- Healthy volunteers
- Not accepted (a condition is required)
- Study type
- Interventional · Phase 2
- Target enrollment
- 150
- US sites recruiting
- 32
- Study start
- August 12, 2026
- Record last updated
- September 4, 2026
Status re-checked against ClinicalTrials.gov within the last 12 hours.
What the study is about
The main purpose of this study is to test the safety and efficacy of study drug for the treatment of chronic low back pain (CLBP). This trial is part of the chronic pain master protocol H0P-MC-CPMP (NCT05986292), which is a protocol to accelerate the development of new treatments for chronic pain.
Being studied: LY4065967; Placebo
Conditions: Chronic Pain; Low Back Pain
Eligibility criteria
Copied from the official record. The study team makes the final decision at screening.
Show full criteria
Inclusion Criteria
- Have a history of low back pain for at least 3 months located between the 12th thoracic vertebra and the lower gluteal folds, with or without radiation
- Have a body mass index at screening of ≤40 kilograms per meter squared (kg/m²).
- Have stable glycemic control as indicated by a glycated hemoglobin (HbA1c) less than or equal to 10 at time of screening
Exclusion Criteria
- Are pregnant or breastfeeding
- Have used a therapeutic injection to the spine in the 3 months prior to screening
- Are using a spinal cord stimulator or dorsal root ganglion stimulator
- Have ongoing complex regional pain syndrome or other concurrent medical conditions that could interfere with the evaluation of CLBP
- Have a history of major spinal deformity, such as spondylolisthesis, spondylolysis, scoliosis, or spina bifida, that causes instability to the spine
- Have an abnormal blood pressure (BP) systolic BP is greater than 140 millimeters mercury (>140 mm Hg) and diastolic BP>90 mm Hg at screening • Have history or current clinically significant cardiac disease, including arrhythmia, aortic aneurysm, heart failure, current electrolyte abnormalities, or any other conditions that could predispose to arrhythmia in the judgement of the investigator
Recruiting US locations
Synexus Clinical Research US, Inc.
Phoenix, AZ 85020
Site contact: Shawn Searle
Arizona Research Center
Phoenix, AZ 85053
Site contact: Louise Taber MD
Artemis Institute for Clinical Research
Riverside, CA 92503
Site contact: Jack Vu
Artemis Institute for Clinical Research
San Diego, CA 92123
Site contact: Stacey Layle
CMR of Greater New Haven
Hamden, CT 06517
Site contact: Joseph Soufer
Bradenton Research Center, Inc.
Bradenton, FL 34205
Site contact: Eric Folkens
Accel Research Sites - DeLand Clinical Research Unit
DeLand, FL 32720
Site contact: Bruce Rankin
K2 MEDICAL Research THE VILLAGES
Lady Lake, FL 32159
Site contact: Craig Curtis
K2 Medical Research ORLANDO
Maitland, FL 32751
Site contact: Brandon Lenox
Merritt Island Medical Research, LLC
Merritt Island, FL 32952
Site contact: David Kirk
Suncoast Research Group
Miami, FL 33135
Site contact: Mark Kutner
New Horizon Research Center
Miami, FL 33165
Site contact: Lazaro Nunez
Suncoast Clinical Research, Inc.
New Port Richey, FL 34652
Site contact: Cathy Barnes
Renstar Medical Research
Ocala, FL 34470
Site contact: David Oliver
Precision Clinical Research
Sunrise, FL 33351
Site contact: Richard Linn
Charter Research - Lady Lake
The Villages, FL 32162
Site contact: Stephen Miller
Conquest Research
Winter Park, FL 32789
Site contact: Anand Patel
North Georgia Clinical Research
Woodstock, GA 30189
Site contact: 678-494-5735
Northwestern University
Chicago, IL 60611
Site contact: Thomas Schnitzer
DelRicht Research
New Orleans, LA 70115
Site contact: Patrick Dennis
Lucida Clinical Trials
New Bedford, MA 02740
Site contact: David Shih
MedVadis Research Corporation
Waltham, MA 02451
Site contact: David DiBenedetto
Great Lakes Research Group, Inc.
Bay City, MI 48706
Site contact: Jeffrey Potts
StudyMetrix Research
City of Saint Peters, MO 63303
Site contact: Timothy Smith
Clinvest Research LLC
Springfield, MO 65807
Site contact: Ralph Duda
Lillestol Research
Fargo, ND 58104
Site contact: Michael Lillestol
META Medical Research Institute
Dayton, OH 45432
Site contact: Priyesh Mehta
DelRicht Research
Tulsa, OK 74133
Site contact: Melita Tate
Altoona Center For Clinical Research
Duncansville, PA 16635
Site contact: Alan Kivitz
FutureSearch Trials of Neurology
Austin, TX 78731
Site contact: John Hudson
Northwest Clinical Research Center
Bellevue, WA 98007
Site contact: Arifulla Khan, MD
Rainier Clinical Research Center
Renton, WA 98057
Site contact: Sheryl Marks
Study contacts (from the official record)
- Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or · 1-317-615-4559 · LillyTrials@Lilly.com
- Physicians interested in becoming principal investigators please contact · clinical_inquiry_hub@lilly.com
Similar studies in Arizona
All pain studies in Arizona →- RecruitingPhase 3
An Open-Label, Safety and Efficacy Study of Cebranopadol in Participants With Acute Pain With Surgical or Non-Surgical Origin
Adneuris Therapeutics, Inc.
- Location
- Phoenix, AZ + 14 other US sites
- Eligibility basics
- Ages 18–75
- RecruitingPhase 3
Efficacy and Safety of VER-01 in the Treatment of Participants With Chronic Painful Lumbosacral Radiculopathy
Vertanical GmbH
- Location
- Tempe, AZ + 22 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 3
Evaluation of Efficacy and Safety of Suzetrigine for Pain Associated With Diabetic Peripheral Neuropathy
Vertex Pharmaceuticals Incorporated
- Location
- Scottsdale, AZ + 57 other US sites
- Eligibility basics
- Ages 18–80
- RecruitingPhase 3
A Study to Evaluate the Effectiveness of IDCT (Intradiscal Cell Therapy) in Subjects With One Level, Symptomatic Mild to Moderate Lumbar Degenerative Disc Disease
DiscGenics, Inc.
- Location
- Phoenix, AZ + 29 other US sites
- Eligibility basics
- Ages 18–75